Rona Yaeger is a translational researcher, Associate Attending Physician with joint appointment to the Gastrointestinal Oncology and Early Drug Development Services in the Department of Medicine, and Associate Director of the Colorectal Cancer Research Center at Memorial Sloan Kettering Cancer Center (MSK). She runs a translational laboratory and maintains an active medical oncology clinical practice at MSK in colorectal cancer.  Her clinical and laboratory research centers on understanding molecular subsets of colorectal cancer to guide the selection of patient populations whose tumors are likely to respond to targeted therapies and to suggest rational therapeutic combinations to enhance the antitumor effect of these agents. She has special expertise in the dysregulation of mitogen-activated protein kinase (MAPK) signaling that commonly occurs in colorectal cancer, resulting from epidermal growth factor receptor (EGFR) activation or activating mutations in RAS or RAF, and the consequences of this dysregulation on parallel and downstream signaling. She has developed and led clinical trials of combination MAPK pathway inhibitors to treat molecularly defined subsets of colorectal tumors, culminating most recently in the successful randomized trial of the KRAS inhibitor adagrasib with or with the EGFR antibody cetuximab. Additionally, She has a detailed knowledge of the genomic landscape of colorectal cancer and oversees the clinical annotation and data collection for small intestinal and colorectal cancers that have been genetically analyzed at MSK.